-
Research Express! Iberdomide in combination with dexamethasone in the treatment of advanced R/R MM is a new progress
Time of Update: 2023-01-06
Multiple myeloma (MM) is characterized by the persistence of minimal residual disease during combination therapy by patients, leading to multiple cycles of remission and recurrence. Each subsequent li
-
The treatment of MM with extramedullary disease gradually improved, and CD38 monoclonal antibody was successfully shortlisted
Time of Update: 2023-01-06
Table 2 RRMM phase II trial results for Dara-DCEP treatment with EMDA study of 24 patients (14 patients, Isa-Pd; 10 cases, Pd) and 19 (12 cases, Isa-Kd; 7 cases, Kd) patients with soft tissue plasmacytoma were analyzed after the fact6, and the prospect of Isatuximab in MM with EMD was also observed 。 The study showed that at a median follow-up of 18.
-
Case evaluation Professor Hou Ming: The combination of two swords and walls has begun to show strength, the blade out of the sheath to accurately block elderly AML, and the treatment of FLT3 mutant AML by geratinib can be expected in the future
Time of Update: 2023-01-06
05×10 9/L, HGB 54g/L, PLT 7×109/L, combined with pulmonary infection, cardiac insufficiency, treated with meropenem, tigecycline, voriconazole, improved, and considered adjusting the 。Myelocytology: CRFlow cytometry: abnormal myeloid cells < 0.
-
Yi Shuo Blood New Time and Space Gathering Chinese and foreign forces, talking about multidisciplinary progress, MM International Exchange Conference was grandly held
Time of Update: 2023-01-06
The content is rich and rewarding, I hope that all colleagues, especially young doctors, will ponder this repeatedly and move forward firmly!At the end of the conference, Professor Chen Wenming, the chairman of the conference, concluded that the conference showed the considerable results of clinical trials, and then sublimated to real-world patient data statistics, and explained in detail the treatment strategies of MM and the development of high-quality real-world research through Sino-foreign exchanges and interdisciplinary sharing.
-
Can autologous hematopoietic stem cell transplantation after first-line therapy prolong the survival of patients with stage II-IV peripheral T-cell lymphoma < 65 years of age?
Time of Update: 2023-01-06
Poke "Read Original" to see moreIn this large study, researchers observed a significant increase in OS rates in patients with advanced PTCL over the past 20 years, but the prognosis remains poor.
-
Can autologous hematopoietic stem cell transplantation after first-line therapy prolong the survival of patients with stage II-IV peripheral T-cell lymphoma < 65 years of age?
Time of Update: 2023-01-06
Poke "Read Original" to see moreIn this large study, researchers observed a significant increase in OS rates in patients with advanced PTCL over the past 20 years, but the prognosis remains poor.
-
Professor Ying Zhitao: The road ahead is also bright, improve the efficacy of CAR-T, solve the dilemma of CAR-T cell therapy, and the 7th International Summit Forum on Anti-leukemia and Lymphoma is on the road
Time of Update: 2023-01-06
On the occasion of the "7th Anti-Leukemia and Lymphoma International Summit Forum and CSCO Leukemia & Lymphoma Expert Committee Tour - Harbin Station", Yimaitong is honored to invite Professor Ying Zhitao of Peking University Cancer Hospital to be interviewed to introduce the current status of CAR-T cell therapy in lymphoma treatment, and talk about the achievements and future exploration directions of the lymphoma department of Peking University Cancer Hospital (Beiwei).
-
Professor Liu Peng from HEMA perspective: RWS in China has identified the benefits of anti-CD20 monoclonal antibody maintenance therapy, providing new evidence for the optimization of FL treatment
Time of Update: 2023-01-06
1Yimaitong: It is understood that your Chinese Academy of Medical Sciences Cancer Hospital Internal Medicine-Lymphoma Treatment Team conducted a real-world study (RWS) with more than 5 years of follow-up for the first time in the era of rituximab in the era of advanced FL in China, and explored the impact of anti-CD20 monoclonal antibody maintenance therapy on patients' treatment outcomes.
-
"Artificial red blood cells" are used in human trials for the first time! Or will revolutionize the treatment of patients with blood disorders!
Time of Update: 2023-01-06
The UK's National Health Service (NHS) has launched a clinical trial with research institutions such as the University of Bristol to inject laboratory-grown red blood cells into humans for the first time.
-
Professor Huang Wenrong: Progress in first-line induction and consolidation therapy for primary central nervous system lymphoma The 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Professor Huang Wenrong said that previous prospective studies have proved that ASCT and whole-brain radiotherapy can significantly improve the median progression-free survival (PFS) of patients with first-line therapy remission of PCNSL compared with non-myeloablative high-dose consolidation chemotherapy.
-
Professor Georg Lenz: Exploring the revolution in DLBCL first-line treatment
Time of Update: 2023-01-06
Question 2: Before Pola reimbursement, what do you think is the most suitable treatment population for untreated DLBCL patients?Professor Georg LenzFrom subgroup analysis data, Pola-R-CHP regimens showed more significant benefit in patients with high-risk factors such as IPI score 3 to 5, age > 60 years, double expression, and ABC subtype, and may be biased towards these patients before reimbursement.
-
Feifan Blood Cloud Classroom November Myeloma Literature Intensive Reading Workshop
Time of Update: 2023-01-06
discussThis study is the largest RRMM WGS data analysis to date (616 total patients) and provides the most comprehensive RRMM genome-wide analysis to date, identifying new RRMM driver genes through coding and noncoding region variants of the genome.
-
Feifan Blood Cloud Classroom November Myeloma Literature Intensive Reading Workshop
Time of Update: 2023-01-06
discussThis study is the largest RRMM WGS data analysis to date (616 total patients) and provides the most comprehensive RRMM genome-wide analysis to date, identifying new RRMM driver genes through coding and noncoding region variants of the genome.
-
Upcoming Conference On November 11, UCLI-CDE invited you to learn about the frontiers of innovative drug research and development
Time of Update: 2023-01-06
In order to further improve the diagnosis and treatment level of leukemia and lymphoma in China, Harbin Hematological Diseases is sponsored by the Chinese Society of Clinical Oncology (CSCO), CSCO Leu
-
Upcoming Conference On November 11, UCLI-CDE invited you to learn about the frontiers of innovative drug research and development
Time of Update: 2023-01-06
In order to further improve the diagnosis and treatment level of leukemia and lymphoma in China, Harbin Hematological Diseases is sponsored by the Chinese Society of Clinical Oncology (CSCO), CSCO Leu
-
Focus on the frontier and help ASCT flourish - CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station) ended perfectly
Time of Update: 2023-01-06
Big coffee gathers, based on clinical practice, sharing academic hot spots! On October 30, 2022, the CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station), hosted by the Chinese Soci
-
Focus on the frontier and help ASCT flourish - CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station) ended perfectly
Time of Update: 2023-01-06
Big coffee gathers, based on clinical practice, sharing academic hot spots! On October 30, 2022, the CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station), hosted by the Chinese Soci
-
Meet Professor Hu Yu: Focus on the quality of life of MM and go to the road of PRO-oriented treatment optimization
Time of Update: 2023-01-06
Multiple myeloma (MM) is a malignant plasma cell disorder that accounts for approximately 10% of hematologic malignancies1. Although the emergence of new drugs and new therapies has improved the survi
-
Professor Li Fei: Seliniso rises to the challenge and breaks the dilemma of multiple myeloma recurrence and incurability!
Time of Update: 2023-01-06
The Guidelines for the Diagnosis and Treatment of Multiple Myeloma in China (2022 Revision)5 points out that 3-4 drugs containing proteasome inhibitors, immunomodulators, daratumumab and nuclear output protein inhibitor celinisol can be selected as much as possible, and salvage autologous hematopoietic stem cell transplantation (ASCT) can be performed if possible 。 BOSTON STUDY7 SHOWED THAT THE MEDIAN PFS IN THE CELINISO PLUS BORTEZOMIB AND DEXAMETHASONE (VD) GROUPS WAS SIGNIFICANTLY LONGER THAN IN THE BORTEZOMIB PLUS DEXAMETHASONE (VD) GROUP (PFS: 13.
-
Professor Wang Jianxiang: Cohesive force, source of the future - the innovation road of Hergilensa cell injection The 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Figure 6 Hergilencel clinical development planThird, the preliminary data of the Hergilencel clinical studyAbout 50%-60% of adult ALL patients will relapse or refractory to treatment, the prognosis of this part of patients is very poor, although new drugs have been approved for marketing in recent years, but the prognosis improvement is not significant, the overall survival is not significantly improved, only 4~7.
